Investment firm upgrades Digirad’s stock 1 week after DMS Health acquisition

Michael Walter | | Radiology Business | Economics

Digirad Corporation has had an eventful October, and the month isn’t even over yet.

Last week, the developer and manufacturer of diagnostic imaging systems entered into a definitive agreement to acquire DMS Health Technologies for $36 million, and now the company’s stock has been upgraded to a “buy” rating by the investment research firm Zacks.

This came after Digirad’s stock was downgraded to “sell” by Zacks back in September.

In a statement about the DMS Health acquisition, Matt Molchan, Digirad’s president and CEO, called the deal a “significant milestone” in the company’s history.

“The integration of DMS Health and Digirad will enable the combined company to expand its range of customers serviced as well as provide significant geographical and service level diversification,” Molchan said. “DMS Health is an ideal strategic fit for us and our commitment to providing healthcare solutions on an as needed, when needed, and where needed basis.”

DMS Health generated more than $65 million in revenue in 2014.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers
Congress ditches doc fix in stopgap end-of-year funding bill
Teleradiology provider inks post-acute care deal worth $1.5M annually
US Radiology Specialists affiliate expands into new market
Radiologist rails against insurer’s refusal to cover key interventional service
Blue Cross Blue Shield affiliate rejects MRI contrast coverage, labeling it ‘investigational’

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.